Type Whole antibody Target angiopoietin 2 CAS Number 1448221-05-3 | Source Humanized ATC code none ChemSpider none | |
 | ||
Vanucizumab (INN) is a humanized monoclonal antibody designed for the treatment of cancer.
Vanucizumab (RG7221) is a bi-specific monoclonal antibody composed of two different heavy chains and two different light chains. One arm of the antibody binds Angiopoietin-2 (Ang2) and the other is based on bevacizumab (Avastin), binding Vascular Endothelial Growth Factor A (VEGF-A). The antibody is designed to inhibit both VEGF-A and Ang2 simultaneously to offer superior clinical benefit compared to VEGF-A inhibition alone.
This drug was developed by Genentech/Roche.
References
Vanucizumab Wikipedia(Text) CC BY-SA